Biogen falls after US FDA declines to approve higher dose of co's genetic disorder drug
View all comments(0)
Shares of drugmaker Biogen BIIB.O fall 1.5% to $137.25 in extended trading
Company says the U.S. FDA has declined to approve higher dose version of its drug for a rare genetic disorder that causes progressive muscle weakness, citing the need for updated technical information in the application
The FDA has requested revisions to the Chemistry Manufacturing and Controls module in its "complete response letter," but did not identify deficiencies in the clinical data supporting the high-dose regimen — BIIB
Company plans to resubmit the application promptly based on readily available information
As of last close, stock down 8.9% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Why SanDisk Stock Could Soar to $4,000?

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

Global First Storage ETF Surges 88% Five Weeks After Listing. Is It Too Late to Buy Now?

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Tradingkey







Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.